Q-omics provides the consensus-scored SNORD101 profile across patient tissues and cancer cell-line models. SNORD101 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORD101 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SNORD101 RNA expression shows 16,810 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SNORD101 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD101 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD101 survival associations across molecular data types. SNORD101 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD101 RNA expression–survival associations across cancer types. High SNORD101 expression shows unfavorable associations in KIRC, ACC, CESC, KICH and THCA, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORD101 RNA expression.
This table summarizes SNORD101 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD101. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD101 shows lower tumor expression in KICH and higher tumor expression in COAD, STAD, LUSC, BLCA and READ. The COAD box plot shows higher SNORD101 RNA expression in tumor versus normal tissue (log2 FC = +1.880, t-test p < 0.001).
This table shows molecular features associated with SNORD101 in patient tissues and cancer cell lines. In patient samples, SNORD101 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
